);

A2 Milk, Wattle step up in China

Infant formula suppliers The A2 Milk Company and Wattle Health Australia have strengthened their regulatory position in the lucrative Chinese market.

A2 Milk’s application to continue selling infant formula products in China has been approved by China’s health regulator, the China Food and Drug Administration (CFDA).

Formula manufacturer Synlait Milk, which has been in partnership with A2 Milk since 2010, submitted the mandatory CFDA application in May.

All infant formula manufacturers must register brands and recipes with the CFDA for products to be imported into China from January 1, 2018.

Chief executive Geoffrey Babidge said the company’s multichannel infant formula strategy in Chinese and English-labelled products had positioned A2 Milk well in the context of current regulatory requirements.

“We look forward to the continued expansion of our business in China following this announcement”, Mr Babidge said in a statement.

Wattle Health has completed its previously announced $5 million acquisition of a five per cent interest in Australian infant formula maker Blend & Pack, which is licensed by the CNCA to produce infant formula range will be the first brand nominated by Blend & Pack for CFDA approval.

As seen in Cairns Post, September 29th 2017.